Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Adding ribociclib to endocrine therapy shows an improvement in invasive DFS in HR+/HER2 BC patientsПодробнее

ADAPT trial: Endocrine + ribociclib vs. chemotherapy in HR+/HER2- early breast cancerПодробнее

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapyПодробнее

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancerПодробнее

Dr. Kelly on the FDA Approval of Ribociclib in HR+ Breast CancerПодробнее

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancerПодробнее

Overall survival results from MONALEESA-2: Endocrine therapy and ribociclib in HR positive and H...Подробнее

Ribociclib in Early Breast Cancer | NEJMПодробнее

Dr. Tripathy on Frontline Endocrine Therapies in HR+ Breast CancerПодробнее

Early Stage Breast Cancer | 2022 OneOncology ConferenceПодробнее

MONARCH 2: abemaciclib added to fulvestrant shows OS benefit in HR+/HER2- advanced breast cancerПодробнее

FDA Approval of Ribociclib for Metastatic Breast CancerПодробнее

Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast...Подробнее

Frontline Therapy in HR-Positive Breast CancerПодробнее

Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trialsПодробнее

NATALEE: ribociclib + NSAI as adjuvant treatment in patients with HR+/HER2− early breast cancerПодробнее

Unmet needs and CDK4/6 inhibitors in HR+/HER2- early breast cancerПодробнее

Dr. Slamon the Phase III Results of MONALEESA-3 Trial in HR+/HER2- Breast CancerПодробнее

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus che...Подробнее